■早期喉鳞状细胞癌(SCC)的治疗包括放疗(RT),放化疗(CRT),和保留喉的手术.在这项研究中,对I期(T1N0)肿瘤患者采用RT治疗早期喉部SCC,对II期(T2N0)肿瘤患者采用CRT和多西他赛(DOC)治疗,并比较治疗结果和化疗效果.
■本研究共纳入78例早期喉部SCC患者。T1N0患者作为门诊患者接受了原发性病变的总剂量为63-70Gy的放射治疗。相比之下,T2N0患者住院并接受CRT治疗,接收66-70Gy的总辐射剂量。多西他赛(DOC,10mg/m2)与放疗同时每周一次静脉内给药,连续6-8周。检查不良事件和生存率以及局部控制率。
■非声门T2N0患者的数量明显高于T1N0患者。尽管所有患者都完成了治疗计划,在T2N0患者中观察到明显更多的3级不良事件,特别是粘膜炎和皮炎,比T1N0患者。5年总生存率,疾病特异性生存率,本地控制率,T1N0和T2N0患者的喉保留率分别为86.1、93.3、88.6和94.3%和85.9、88.0、93.1和93.1%,分别。
■使用多西他赛的CRT在T2N0肿瘤患者中显示出最佳的治疗效果,具有较高的局部控制率,有效的喉部保存,和相对较少的不良事件。
UNASSIGNED: Treatments for early laryngeal squamous cell carcinoma (SCC) include radiotherapy (RT), chemoradiotherapy (CRT), and larynx-preserving surgery. In this study, early laryngeal SCC was treated with RT in patients with stage I (T1N0) tumors and with CRT and docetaxel (DOC) in patients with stage II (T2N0) tumors and the treatment results and effectiveness of the chemotherapy were compared.
UNASSIGNED: A total of 78 patients with early-stage laryngeal SCC were enrolled in this study. The T1N0 patients received radiation for the primary lesions as outpatients at a total dose of 63-70 Gy. By contrast, the T2N0 patients were hospitalized and treated with CRT, receiving a total radiation dose of 66-70 Gy. Docetaxel (DOC, 10 mg/m2) was administered intravenously once a week for 6-8 consecutive weeks concurrently with radiotherapy. The adverse events and survival rates with local control rates were examined.
UNASSIGNED: The number of non-glottic T2N0 patients was significantly higher than that of T1N0 patients. Although all patients completed their treatment schedule, significantly more grade 3 adverse events were observed in the T2N0 patients, in particular mucositis and dermatitis, than in T1N0 patients. The 5-year overall survival rate, disease specific survival rate, local control rate, and laryngeal preserve rate of the T1N0 and T2N0 patients were 86.1, 93.3, 88.6, and 94.3% and 85.9, 88.0, 93.1, and 93.1%, respectively.
UNASSIGNED: CRT with docetaxel showed the best therapeutic outcomes for the treatment of laryngeal SCC in patients with T2N0 tumours, with a higher local control rate, effective laryngeal preservation, and relatively few adverse events.